OPINION Immunotherapy in kidney cancer: the past, present, and future
INTRODUCTION
Each year, we expect to diagnose around 60 000 patients with kidney cancer/renal cell carcinoma (RCC) and around 14 000 patients are expected to die from metastatic RCC (mRCC) (SEER) in the United States. Kidney cancer is different from other epithelial tumors in that it is inherently resistant to cytotoxic chemotherapy and effective systemic treatments have been elusive for long period of time. However, insights into the genetic characteristics of clear-cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, has led to an unprecedented success of small molecule tyrosine kinase inhibitors and monoclonal antibodies targeting the vascular-endothelial growth factor pathway, which suppresses tumor angiogenesis. The sequential use of these targeted therapies has led to an impressive improvement in life expectancy for patients with metastatic kidney cancer [1] .
Another distinguishing feature of ccRCC is the perceived immunogenicity of this tumor type. Albeit rare, tumor regressions of metastatic deposits after nephrectomy have been described and ccRCC is the only other tumor type besides melanoma for which interleukin-2 (IL-2) has been approved since 1992 [1] .
The goal is to provide some basic principles in tumor immunology and provide an overview of first, first-generation immunotherapies such as high dose IL-2 and IFN-a, second, the current state of immune checkpoint inhibition in RCC, and third, take a look at potential strategies for improving immunotherapies for the treatment of kidney cancer in the future.
BASIC IMMUNOLOGICAL PRINCIPLES
A lot has been learned in the field of cancer immunology over recent decades and has been captured well in the cancer immunity cycle as described by Chen and Mellman [2] : principally, the adaptive immune response requires the presentation and education about its targets. Turnover of cancer cells and associated cell death leads to the release of tumor-associated antigens, typically overexpressed or mutated proteins, which are then captured by professional antigen presenting cells, the dendritic cells. These cells migrate to secondary lymphoid organs whereas effector T cells are being educated and activated, which in turn will traffic throughout the host, infiltrate tumors and recognize and kill cancer cells expressing specific tumor-associated antigens or mutated proteins. They do so by recognizing respective peptides which are presented through the MHC I complex to the cognate T cell receptor. This leads to further activation and expansion of reactive T cell clones which engage their targets release an arsenal of cytotoxic molecules like granzyme and perforin in close proximity. This can release further antigens, which in the best case scenario leads to the detection of several tumorspecific epitopes ('epitope spreading'), broadening of the immune response and potential elimination of the tumor cells. Importantly, however, at virtually each point of the immunity cycle counterregulatory mechanisms exist which can dampen or suppress the immune response to keep us protected from an overshooting immune response. These breaks of the immune system, often referred to as 'immune checkpoints' can be usurped by the tumor and its associated microenvironment to protect it from an effective immune response. Interestingly, the recent revolution in immuno-oncology has been primarily achieved by targeting and releasing the breaks of the immune system (immunecheckpoint inhibitors). The opposite, activating the immune system with tumor vaccines, for example, has been met primarily with failures, although sipuleucel T, a dendritic cell-based vaccine has been approved for the treatment of prostate cancer. Other agents, like the cytokine interferon alpha and interleukin have T cell activating functions, and been used with moderate success for the treatment of renal cell carcinoma.
The past
Before the advent of targeted therapy, that is, vascular endothelial growth factor (VEGF) pathway inhibitors, cytokines dominated the treatment for metastatic ccRCC. The most widely used agent was interferon alpha (IFNa) which produced a moderate response rate and a moderate effect on median overall survival (mOS) when compared with chemotherapy or progesterone and remained around 1 year. Most responses to IFNa were of limited duration and complete responses were only seen in a small number of patients. Additionally, flu-like symptoms and liver toxicity made the chronic use of this agent challenging.
The other cytokine, which has been approved for kidney cancer in 1992, is IL-2. This cytokine, when given intravenously in high doses can produce an overall responses rate of 20-25% with 8-10% of complete responses [3 & ]. Clinical benefit was mostly limited to responders and an improvement in mOS or median progression-free survival (mPFS) has not been observed. However, the duration of responses and the lack of recurrence for most complete responders has led to the approval of this agent for kidney cancer and melanoma alike. The major drawback of IL-2, which performs best when administered intravenously in high doses is its acute toxicity. The administration requires inpatient, often intensive care unit, support for the management of edema, capillary leak, severe hypotension, and multiorgan failure. Thus, the administration of this potentially curative treatment is typically restricted specialized academic center and is only offered to a small minority of patients with metastatic kidney cancer.
The present
Modern immunotherapy, specifically immune checkpoint inhibitors such as anti-programmed death receptor 1 (anti-PD1) and anti-programmed death receptor ligand 1 (anti-PDL1) antibodies are challenging the current treatment paradigm of most solid tumors, and in particular kidney cancer [3 & ]. One of these drugs, the anti-PD1 antibody
KEY POINTS
Kidney cancer has a long treatment history with immunological agents like interferon and interleukin-2 (IL-2).
The current immunotherapy in kidney cancer is dominated with programmed death receptor 1 (PD1) monotherapy, but will be replaced by PD1/ programmed death receptor ligand 1 (PDL1) combination therapies in the near future.
Rational combination immunotherapies in kidney cancer comprise the addition of VEGF. nivolumab, has been FDA approved for kidney cancer at the end of 2015.
The primary endpoint of the pivotal 821 previously treated patient trial leading to approval of this agent for kidney cancer was mOS. Patients treated with nivolumab experienced a mOS of 25 months versus 19.6 months for patients treated with everolimus. 70% of patients were treated in the second line [3 & ]. Importantly, nivolumab was very well tolerated and the immune-related side-effects typically responded well to the treatment with corticosteroids. In fact, quality of life scores improved for patients treated with nivolumab and were superior to the treatment with everolimus, an mammalian target of rapamycin (mTOR) inhibitor. The success of PD1/PDL1 pathway inhibitors has established immunotherapy as an indisputable pillar for the treatment of metastatic kidney cancer and immune checkpoint inhibitors like nivolumab will form the backbone of future, more effective combination therapies [4 && ,5]. Both, patients whose tumor tissue stained positive for the PD1 ligand PDL1 or were negative for PDL1 expression, benefited from the treatment of nivolumab. Therefore, there is currently no rational patient selection tool for patients who benefit from PD1 inhibition with nivolumab or not [3 & ].
The future
The most promising combination therapies will fall into one of the three categories [4 && ,5]:
(1) PD1/PDL1 inhibition plus other checkpoint inhibitors, T cell agonists or microenvironment modifying agents, (2) PD1/PDL1 inhibition plus (personalized) vaccination approaches, (3) PD1/PDL1 inhibition plus adoptive T cell therapy.
CHECKPOINT INHIBITOR COMBINATION THERAPIES
Over the next decade, the immunotherapy trials in kidney cancer will be dominated by combination studies of PD1/PDL1 inhibitors with other immune modifying agents such as VEGF pathway, other immune checkpoint inhibitors like anti-CTLA4 as well as the T cell agonists 41BB and Ox40. For example, the dual immune checkpoint inhibition with the PD1 inhibitor nivolumab and the CTLA4 inhibitor ipilimumab (Ipi) has demonstrated encouraging activity in ccRCC and other solid tumors. nivolumab and Ipi target different compartments of the immune response, and thus synergize in their ability to unleash the immune response [6] . We have treated almost 100 patients in two different dosing cohorts with nivolumab and Ipi [7, 8] . Both dosing cohorts (3 mg/kg nivolumab, 1 mg/kg Ipi (N3I1) and 1 mg/kg nivolumab, 3 mg/kg Ipi (N1I3)) have shown a remarkable activity with 40% of patients experiencing durable responses in both arms. However, the treatment arm with the lower dose of Ipi was better tolerated with one-third of patients experiencing grade 3/4 treatment-related toxicity versus two-thirds of patients on the N1I3 arm. A large phase III trial (Checkmate 214, NCT02231749) has accrued and pivoted this combination against sunitinib in the first line setting. Results are expected as early as 2017 and could be practice changing.
As ccRCC is 'addicted' to the VEGF pathway, the combination with VEGF inhibitors presents an attractive strategy. In addition to the expected antitumor from the effect on the tumor vasculature, inhibitors of the VEGF pathway have the potential to augment an immune response by suppressing myeloid-derived suppressor cells and T regulatory cells [9, 10] . Early combination trials with PD1 inhibitors have demonstrated promising clinical activity albeit limiting liver toxicity was observed with the less selective tyrosine kinase inhibitors sunitinib and pazopanib [11] . Several clinical trials testing more selective VEGF pathway inhibitors like bevacizumab or axitinib in combination with the PDL1 inhibitors atezolizumab [12] (NCT02420821) and avelumab (NCT02493751) or the PD1 inhibitor pembrolizumab [13] (NCT02133742) are underway and appear to exhibit a superior side-effect profile.
Stimulating antibodies directed against activators of the T cell response like 41BB/CD137 and Ox40/CD134 are promising and have entered clinical development. Early clinical trials studying the combination of the 41BB agonist utomilumab with the PD1 inhibitor pembrolizumab has shown promising tolerability and efficacy signals (NCT02179918) [14] . Similarly, a phase I trial combining the anti-Ox40 antibody MOXR0916 and the PDL1 inhibitor atezolizumab has shown a good safety profile and encouraging signs of activity (NCT02410512) [15] .
VACCINATION STRATEGIES
It has become increasingly clear that immune checkpoint inhibitors essentially require a preestablished immune response. In the past, vaccination strategies alone have not produced the desired results in the treatment of cancer; however, they do have the potential to synergize with immune checkpoint inhibitor therapy. This hypothesis will undoubtedly lead to a renaissance of these approaches across solid and liquid tumors. Two principle approaches can be pursued.
The first approach is designed to turn a cancer deposit into an in-situ vaccine by using focally ablative techniques such as stereotactic radiation or cryotherapy [16] . One of the critical questions is whether focal therapy in the context of immune checkpoint blockade can unleash a clinically significant abscopal effect [17] and several trials with kidney cancer patients are underway to approach this question (e.g., NCT02599779 and NCT02781506).
Recently, the results from a phase III open-label trial with metastatic HLA-A Ã 02 positive RCC was reported [18] . Following one cycle of sunitinib, patients were randomized 3:2 up to 10 intradermal vaccinations of IMA901, a peptide vaccine, plus 75 mg GM-CSF plus sunitinib (50 mg; standard 4 weeks on/2 weeks off) versus sunitinib alone. Patients in the vaccine arm were given a single infusion of cyclophosphamide 3 days before the first vaccination to reduce regulatory T cells. Unfortunately, the study did not meet its endpoint and leaves us wondering if the addition of a PD1/PDL1 inhibitor could have resulted in a different outcome.
The results from another phase III vaccination trial with AGS-003, an autologous tumor RNA pulsed dendritic cell vaccine are eagerly awaited (NCT01582672). This trial randomized patients with cytoreductive nephrectomy receive either sunitinib alone or in combination with the dendritic cell vaccine AGS-003. This trial was designed before the approval of the PD1 immune checkpoint inhibitor nivolumab in RCC and the efficacy of the agent AGS-003 may need to be revisited in combination with a PD1 or PDL1 inhibitor.
In the future, vaccination approaches will likely be further tailored to the patient's mutanome and tumor-associated antigen profile with the goal to individualize treatments and thus maximize the potential benefit [19] [20] [21] .
In the past, vaccination approaches have often used allogeneic cell lines or tumor-associated antigens [22] . These are typically shared among individual patients allowing a convenient 'off the shelf' approach (e.g., CA9) [23] . In contrast, personalized approaches of vaccination are tailor-made for each patient and in spite of being more laborious, hold great potential. Recent technical advancements have enabled the immunotherapy community to identify immunogenic peptides from the mutanome, or deliver RNA vaccines, such vaccines could induce enhanced tumor-specific immune response since neoantigens are mutationderived antigens that can be recognized by high affinity T cells [19, 21] . Additionally, autologous tumor cells/lysates could be used and augmented with novel adjuvants such as toll like receptor or stimulator of interferon genes agonists, thus increasing the likelihood of the initial, critical immune response [24] . These whole cell vaccines, similar to in-situ vaccination approaches, can provide a source for the full repertoire of the patient-specific tumor antigens, ranging from overexpressed, nonmutated proteins, including cancer testis antigens, to private, mutation-driven neoantigens.
ADOPTIVE T CELL THERAPIES FOR RENAL CANCER
Other emerging opportunities for the immunotherapy of kidney cancer are based on the cellular therapy with either genetically modified and redirected T cells (e.g., CAR T-cells) or expanded tumor infiltrating lymphocytes [25] . Although CAR T-cells are showing potent antitumor activity in hematological malignancies, their utility in solid tumors, which typically lack highly specific or exclusive antigens (like CD19) and expendable target tissues (B cells), is somewhat questionable. For example, a clinical trial with CA9 redirected T cells showed limiting, on-target, biliary toxicity in renal cell carcinoma patients and its development has been abandoned [26] . However, 'natural' tumor-specific T-cells, which recognize (often unknown) tumor antigens, can be expanded and adoptively transferred thus offering considerable opportunities for kidney cancer patients [27, 28] .
The classic, adoptive T cells transfer requires the resection of metastatic lesions and the culture and expansion of the tumor-infiltrating lymphocytes [27] . While this approach has historically been a complex and resource intensive undertaking that has been primarily restricted to the NCI (Dr Rosenberg, melanoma patients), but the opportunity is emerging to outsource the production of the cellular product to a commercial partners (e.g., Lion Biotechnologies). This could potentially facilitate and expand the implementation of this approach for other diseases. However, lymphocytes derived from cancers other than melanoma have been first, more difficult to expand and second, have shown a lower rate of tumor-specific cytolytic activity [27] . Thus, other sources of tumor-specific T cells may need to be considered.
Studies in cancer patients have defined the human bone marrow as a harbor and reservoir for tumor Ag-specific memory CD8 T cells with potent effector function in a variety of diseases ranging from breast cancer, pancreatic cancer, and melanoma to multiple myeloma [29] [30] [31] . The quality of these memory cells with regard to their polyclonal, endogenous, tumor specificity differs significantly from regular expanded peripheral blood lymphocytes, which lack intrinsic tumor specificity. Therefore, novel sources for tumor reactive T cells in combination with industrial partners for T cell production might lead to a more widespread use of adoptive T cell therapy.
CONCLUSION
The rapidly evolving field of immunooncology is producing already significant clinical benefits for patients with kidney cancer. However, the full potential of immunotherapy has not been reached and will require an assessment of the host antitumor immune response and the tailored, rational design of combination therapies. Although immunotherapy, like any therapy, will not work for everyone, its potential is enormous and will likely dominate therapeutic approaches in the future.
